Evidence map›Paper›PMID 42231627›Full record

ArticleMicrocirculation (New York, N.Y. : 1994)2026

GLP-1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels.

Mary E Schulz, Victoria L Akerstrom, Joseph H Dayan, Jorge A Castorena-Gonzalez

Abstract read
In one paragraph

Article in Microcirculation (New York, N.Y. : 1994), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Mary E SchulzDepartment of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Victoria L AkerstromDepartment of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Joseph H DayanThe Institute for Advanced Reconstruction, Glen Rock, New Jersey, USA.
Jorge A Castorena-GonzalezDepartment of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, USA.

Funding

Trpv4 regulation of lymphatic vascular function: Implications in metabolic syndromeR01HL168568 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI Jorge Augusto Castorena · 2023 to 2026
$1.9M
Unraveling the mechanisms behind lymphatic dysfunction in obesity: are weight-loss drugs effective at restoring lymphatic function?F31HL179791 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI Mary E Schulz · 2025 to 2026
$100k
NHLBI NIH HHS F31 HL179791NHLBI NIH HHS R01 HL168568NIH HHS F31HL179791NIH HHS R01HL168568
6 · The paper itself

Abstract

objectivesRecent clinical studies have suggested that glucagon-like peptide-1 receptor (GLP-1R) agonists may be effective therapies to treat or reduce the risk of developing secondary lymphedema. In this study, we aimed to (1) determine if GLP-1Rs are present in the lymphatic vasculature and characterize their expression, and (2) assess the effects of GLP-1R agonism on the contractile function of collecting lymphatic vessels.

methodsWe assessed the expression of GLP-1Rs in and around the lymphatic vasculature by single-cell RNA sequencing and fluorescence confocal microscopy, and evaluated the direct effects of GLP-1R agonist, semaglutide, on modulating lymphatic contractility using pressure myography.

resultsExpression of Glp1r (encoding GLP-1Rs) was detected exclusively in lymphatic endothelial cells. Pharmacological activation of GLP-1Rs led to robust vasodilation and an increase in the pumping capacity of isolated collecting lymphatics from WT, diet-induced obese, and hypercholesterolemic ApoE KO mice. The GLP-1R-mediated response was in part facilitated by nitric oxide and its potential interaction with NaV channels; however, additional signaling remains to be elucidated.

conclusionsOur results revealed a direct, beneficial effect of GLP-1R agonism on lymphatic pumping capacity mediated by robust vasodilation, allowing lymphatics to accommodate and displace larger fluid volumes while maintaining strong and highly efficient contractions.

Indexed as

Endothelium, LymphaticGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsLymphatic VesselsSemaglutideAnimalsMaleMiceMice, KnockoutVasodilationGlp1r protein, mouseGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsSemaglutideGLP‐1Rlymphatic vesselsscRNAseqsecondary lymphedemasemaglutide

Identifiers

PMID42231627
PMCPMC13436613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.